LON:AVO Advanced Oncotherapy Share Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Advanced Oncotherapy PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 31 0.00 (0.00 %) (As of 09/21/2020 12:00 AM ET) Add Compare Share Today's Range 30.50Now: GBX 31▼ 3250-Day Range 25MA: GBX 29.92▼ 3452-Week Range 0.29Now: GBX 31▼ 44Volume79,272 shsAverage Volume130,793 shsMarket Capitalization£94.98 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesHeadlines Advanced Oncotherapy PLC, together with its subsidiaries, focuses on providing radiotherapy systems for the treatment of cancer. The company operates through two segments, Proton Therapy and Healthcare Related Properties. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. The company also rents a medical facility. It has operations in the United Kingdom, Switzerland, and the Unites States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy PLC was incorporated in 2005 and is headquartered in London, the United Kingdom.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAdvanced Oncotherapy has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 155, Advanced Oncotherapy has a forecasted upside of 400.0% from its current price of GBX 31.Amount of Analyst CoverageAdvanced Oncotherapy has received no research coverage in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesAdvanced Oncotherapy has received 188 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAdvanced Oncotherapy has received 243 “underperform” votes. (Add your “underperform” vote.)Community SentimentAdvanced Oncotherapy has received 56.38% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Advanced Oncotherapy and other stocks. Vote “Outperform” if you believe AVO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AVO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAdvanced Oncotherapy does not currently pay a dividend.Dividend GrowthAdvanced Oncotherapy does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Advanced Oncotherapy insiders have bought more of their company's stock than they have sold. Specifically, they have bought £1,948,050 in company stock and sold GBX 0 in company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Advanced Oncotherapy is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Advanced Oncotherapy is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdvanced Oncotherapy has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.74 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Medical Devices Sub-IndustryN/A SectorMedical Current SymbolLON:AVO Previous Symbol CUSIPN/A CIKN/A Webwww.advancedoncotherapy.com Phone+44-20-36178728Debt Debt-to-Equity Ratio108.32 Current Ratio3.43 Quick Ratio0.83Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 1.10 per share Price / Cash Flow28.18 Book ValueGBX 17.60 per share Price / Book1.76Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees93 Outstanding Shares306,371,008Market Cap£94.98 million Next Earnings DateN/A OptionableNot Optionable GBX 31 0.00 (0.00 %) (As of 09/21/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive AVO News and Ratings via Email Sign-up to receive the latest news and ratings for AVO and its competitors with MarketBeat's FREE daily newsletter. Advanced Oncotherapy (LON:AVO) Frequently Asked Questions How has Advanced Oncotherapy's stock price been impacted by Coronavirus (COVID-19)? Advanced Oncotherapy's stock was trading at GBX 32.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AVO shares have decreased by 4.6% and is now trading at GBX 31. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Advanced Oncotherapy? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advanced Oncotherapy in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Advanced Oncotherapy. How were Advanced Oncotherapy's earnings last quarter? Advanced Oncotherapy PLC (LON:AVO) released its earnings results on Monday, June, 29th. The company reported ($9.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($8.90) by $0.93. View Advanced Oncotherapy's earnings history. What price target have analysts set for AVO? 1 brokerages have issued 12 month target prices for Advanced Oncotherapy's shares. Their forecasts range from GBX 155 to GBX 155. On average, they anticipate Advanced Oncotherapy's share price to reach GBX 155 in the next year. This suggests a possible upside of 400.0% from the stock's current price. View analysts' price targets for Advanced Oncotherapy. Who are some of Advanced Oncotherapy's key competitors? Some companies that are related to Advanced Oncotherapy include Neuronetics (VMD), Creo Medical Group (CREO), Hamilton Thorne (HTL), Medica Group (MGP), Patient Home Monitoring (PTQ), MRI Interventions (CLPT), Electromed (ELMD), Electromed (ELMD), Titan Medical (TMD), Polarean Imaging (POLX), MRI Interventions (MRIC), Protech Home Medical (PHM), Inspiration Healthcare Group (IHC), Delcath Systems (DCTH) and Kromek Group (KMK). View all competitors. What other stocks do shareholders of Advanced Oncotherapy own? Based on aggregate information from My MarketBeat watchlists, some companies that other Advanced Oncotherapy investors own include UK Oil & Gas (UKOG), Avesoro Resources (ASO), Oxford BioMedica (OXB), BMR Group (BMR), GW Pharmaceuticals PLC- (GWPH), Lancashire (LRE), Sirius Minerals (SXX), Renishaw (RSW), Scancell (SCLP) and Tullow Oil (TLW). Who are Advanced Oncotherapy's key executives? Advanced Oncotherapy's management team includes the following people: Dr. Michael Jeffrey Sinclair, Exec. Chairman (Age 76)Mr. Nicolas Serandour, CEO & Exec. DirectorMr. Ed Lee, COO & Sr. VP of OperationsMr. Graham Pughe, Sr. Vice-Pres, Accounting & ITMs. Geraldine Poindron, Corp. Fin. Mang. What is Advanced Oncotherapy's stock symbol? Advanced Oncotherapy trades on the London Stock Exchange (LON) under the ticker symbol "AVO." How do I buy shares of Advanced Oncotherapy? Shares of AVO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Advanced Oncotherapy's stock price today? One share of AVO stock can currently be purchased for approximately GBX 31. How big of a company is Advanced Oncotherapy? Advanced Oncotherapy has a market capitalization of £94.98 million. Advanced Oncotherapy employs 93 workers across the globe. What is Advanced Oncotherapy's official website? The official website for Advanced Oncotherapy is www.advancedoncotherapy.com. How can I contact Advanced Oncotherapy? Advanced Oncotherapy's mailing address is Third Fl Clearwater HSE, 4-7 Manchester Street, LONDON, W1U 3AE, United Kingdom. The company can be reached via phone at +44-20-36178728. This page was last updated on 9/21/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
